Becton Dickinson and Company (BDX) — ESG & Values Scores

Environment story

BDX demonstrates moderate environmental performance with significant regulatory compliance challenges outweighing sustainability commitments. Ethylene oxide emissions and sterilization operations present material environmental risks and ongoing regulatory burdens. No disclosed net-zero target year identified in filings. Scope 1, 2, and 3 emissions data not provided in source documents, limiting quantitative assessment. The company has proactively installed fugitive emissions controls at two sterilization facilities and faces substantial compliance costs under EPA NESHAP and Pesticide Registration Review requirements. Climate change risks acknowledged but mitigation strategy remains operationally focused rather than transformational. No evidence of renewable energy transition or carbon offset reliance detected.

Criticisms on file

Ethylene oxide regulatory escalation: EPA issued final NESHAP regulation (April 5, 2024) requiring enhanced emissions controls; separate Pesticide Registration Review Decision (January 14, 2025) imposes stricter occupational exposure limits, engineering controls, and continuous monitoring. Compliance deadlines range 60 days to 10 years. Company faces potential suspension of sterilization operations if non-compliant.
Source: BDX 10-K Item 1A Risk Factors and Regulation section; EPA NESHAP Final Rule April 5, 2024; EPA Pesticide Registration Review Decision January 14, 2025
No disclosed net-zero emissions target or climate transition plan in 10-K or proxy materials. Risk factors acknowledge climate change impacts but lack specific 2030/2035/2045 reduction targets.
Source: BDX 10-K Item 1A 'Climate change and related sustainability efforts' section; absence in Item 1 Business and MD&A
Water and resource consumption risks acknowledged for manufacturing operations but no quantified water impact assessments or conservation targets disclosed.
Source: BDX 10-K Item 1A Risk Factors; 'access to certain natural resources, such as water, could impact our manufacturing operations'

Disclosed initiatives

Ethylene Oxide Emissions Controls Installation

Proactively installed fugitive emissions controls at sterilization facilities in East Columbus, NE and Sandy, UT; implementing additional changes to comply with EPA NESHAP by April 2028 and Pesticide Registration Review requirements

Reduces direct operational emissions but involves significant capital expenditure and ongoing compliance costs; two-year presidential exemption granted July 2025
Business Continuity Planning for Sterilization Operations

Maintains contingency plans to mitigate sterilization operation disruptions from regulatory requirements and supply chain constraints

Defensive posture; does not advance decarbonization targets

Social story

BDX presents a mixed social profile with formalized workforce development and diversity programs offset by regulatory compliance obligations and product liability exposure. CEO-to-worker pay ratio not disclosed but compensation philosophy articulated as competitive and performance-aligned. Global workforce of 72,000 across 61 countries with stated commitment to diversity and inclusion through nine Associate Resource Groups. No documented union-suppression activities or major strikes in past 24 months. Limited supply-chain human-rights disclosure; conflict minerals and labor practices in high-risk geographies (cobalt sterilization supplies, DRC sourcing) not fully audited. Plant safety records and turnover rates not quantified in filings.

Criticisms on file

Product liability litigation relating to hernia repair implants, surgical continence and pelvic organ prolapse products for women, vena cava filters, and implantable ports. Class action and MDL potential disclosed; damages ranges unestimated.
Source: BDX 10-K Item 1A 'We are subject to lawsuits' section; Note 6 consolidated financial statements
FDA Consent Decree and Warning Letters affecting manufacturing quality at CareFusion 303 subsidiary (infusion pumps, dispensing systems). Form 483 inspections (2020, 2024) identified quality system, MDR reporting, and complaint handling deficiencies. December 2021 Non-Compliance Letter; November 2024 Dispensing Warning Letter; ongoing corrective action audits through 2025.
Source: BDX 10-K Item 1A 'Consent Decree with FDA' and 'FDA Warning Letters' sections
Supply chain human-rights risk: Company acknowledges sole-source reliance on certain materials (e.g., cobalt for sterilization), creating exposure to labor and environmental risks in high-risk geographies. No disclosed third-party audit results or remediation program for DRC cobalt or other conflict minerals.
Source: BDX 10-K Item 1A 'A reduction or interruption in the supply of certain raw materials and components' and 'Interruption of our manufacturing or sterilization operations' sections
Labor cost inflation and turnover risk: Company acknowledges 'sustained labor shortage or increased turnover rates' leading to higher wages, overtime, and recruitment costs. Specific turnover rates not disclosed.
Source: BDX 10-K Item 1A 'We need to attract and retain key employees to be competitive' section

Disclosed initiatives

BD University and Leadership Development

Internal learning curriculum providing core and management capabilities; nomination-based executive acceleration programs in partnership with external experts; succession planning focus

Supports career progression and retention of skilled workforce
Total Rewards Program

Market-competitive pay, broad-based stock grants, bonuses, healthcare, retirement savings, paid time off, family leave, flexible work schedules, on-site health centers, mental health support; periodic audits and benchmarking for compensation equity

Comprehensive benefits structure; company states focus on affordability for workers earning $55,000/year or less
Culture of Inclusion and Associate Resource Groups

Nine ARGs with executive sponsors; diversity and inclusion initiatives; paid volunteer opportunities; matching gift program; diversity supplier program mentioned in Corporate Sustainability Report context

Foundational DEI infrastructure; 2025 recognition as best place to work for disability inclusion
Periodic Compensation Disparity Audits

Company conducts 'comprehensive audits, internal and external analyses, salary benchmarking and assessments to identify and remedy compensation disparities'

Proactive pay equity framework

Governance story

BDX demonstrates strong governance fundamentals with 12 of 13 directors independent (92%), majority voting standard, robust lead director structure, and annual board self-evaluation. No dual-class share structure identified. Board includes recent appointments (2025) with sector expertise (Gregory J. Hayes from RTX, Robert L. Huffines from J.P. Morgan). Mandatory director retirement and overboarding policies in place. Proxy access bylaws and shareholder right to act by written consent enabled. No poison pill. Material governance concern: ongoing FDA Consent Decree and two active Warning Letters (Dispensing and Specimen Management) reflecting significant regulatory non-compliance history at CareFusion 303 subsidiary—potential for expanded consent decree terms or manufacturing shutdown authority. Lobbying expenditures not separately disclosed; political contribution restrictions stated. Antitrust and healthcare fraud litigation risks disclosed but not quantified.

Criticisms on file

FDA Consent Decree: CareFusion 303 subsidiary operating under amended consent decree since 2007/2009 for infusion pump manufacturing. December 2021 Non-Compliance Letter identified corrective actions as inadequate (complaint handling, CAPA, design verification, MDR). Independent audits extended through 2025. Potential FDA authority to order cessation of infusion pump manufacturing, recall products, and levy penalties up to $15 million annually.
Source: BDX 10-K Item 1A 'Consent Decree with FDA' section; Item 1 Business 'Regulation' subsection
FDA Warning Letter (November 22, 2024) for Dispensing Systems: CareFusion 303 Dispensing quality management system (San Diego, CA facility) cited for violations of quality system regulations, MDR regulation, and corrections/removals reporting. Company recorded estimated liability for remediation costs; amount could exceed accrual. No assurances given regarding adequacy of corrective actions or absence of future regulatory action (seizure, injunction, civil penalties).
Source: BDX 10-K Item 1A 'FDA Warning Letters' section; Note 6 consolidated financial statements reference
FDA Warning Letter (January 11, 2018) for former Preanalytical Systems (now Specimen Management): Alleged violations of quality system regulations. March 2020 follow-up inspection classified as 'Voluntary Action Indicated.' December 2022 inspection resulted in no observations. Ongoing commitment to file remaining 510(k)s; as of September 30, 2025, eight FDA clearances received. Residual compliance risk.
Source: BDX 10-K Item 1A 'FDA Warning Letters' section
Antitrust and securities litigation: Company disclosed as defendant in 'purported class action lawsuits for alleged antitrust violations and violations of federal securities laws.' Specific details deferred to Note 6; no materiality quantification provided. Government investigations ongoing regarding alleged violations in connection with federal/state healthcare programs, federal securities laws, and sales/marketing practices.
Source: BDX 10-K Item 1A 'We are subject to lawsuits' section
Absence of quantified lobbying disclosure: Proxy materials reference 'Restrictions on corporate political contributions' but do not disclose annual lobbying expenditures or targeted regulatory positions on climate, healthcare, or consumer protection issues. Potential misalignment with environmental commitments not assessed.
Source: BDX Proxy Statement, Governance Best Practices section; no lobbying expenditure line item in 10-K disclosed sections

Disclosed initiatives

Board Composition and Independence

12 of 13 director nominees independent; annual election of directors; majority voting standard; mandatory director retirement policy; rigorous annual self-evaluation and renomination process

Aligns with best practices; strong governance structure
Lead Director Structure and Board Leadership

Robust lead director role separate from Chairman/CEO; Lead Director and Governance Committee Chair conduct annual board self-evaluation

Enhances oversight independence
Shareholder Rights and Engagement

Proxy access bylaws; right to call special meetings; right to act by written consent; annual shareholder engagement process; restrictions on corporate political contributions; annual charitable contributions reporting

Strengthens shareholder voice and transparency
Director and Executive Officer Share Ownership Requirements

Ownership guidelines in place; disclosure of beneficial holdings by directors and management

Aligns leadership interests with shareholder value
FDA Consent Decree Compliance Program and Independent Expert Audits

CareFusion 303 retained independent expert to conduct periodic audits of infusion pump quality management system through 2025; comprehensive corrective action plan (CAP) updated per FDA feedback; ongoing engagement with regulatory agencies

Reactive remediation; does not prevent underlying quality management failures

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Becton Dickinson and Company. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Becton Dickinson and Company in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)